Education · Tier 1

· Last Reviewed May 15, 2026· PSI Editorial Board· Independent

Where Did Peptide Therapy Research Come From?

The historical reference for international peptide research anchored in academic laboratory programs and FDA-approved peptide drug development history.

Peptide therapy traces back to multiple academic laboratories worldwide.

The GLP-1 receptor agonist class originated in academic discovery in the 1980s.

The anabolic osteoporosis peptide class derives from parathyroid hormone research.

1980s

GLP-1 Discovery

Foundational GLP-1 discovery research by Joel Habener and Daniel Drucker laboratories in the 1980s

1970s

Khavinson Lab

Khavinson laboratory longevity research at St. Petersburg Institute of Bioregulation and Gerontology since the 1970s

1990s

Sikiric BPC-157

Sikiric laboratory BPC-157 research at University of Zagreb since the 1990s

35 Countries

Zadaxin Approval

Goldstein laboratory thymosin alpha-1 program led to Zadaxin approval in approximately 35 countries

Quick Answer

Peptide therapy traces back to multiple academic laboratories worldwide. The research landscape spans GLP-1 receptor agonist discovery, parathyroid hormone analog development, longevity peptide research, tissue repair peptide research, and immune peptide research.

GLP-1 receptor agonist development originated in academic laboratories in the 1980s. Joel Habener at Massachusetts General Hospital conducted foundational glucagon and GLP-1 discovery research. Daniel Drucker at University of Toronto extended GLP-1 physiology and clinical translation. The academic foundation led to FDA-approved peptide drugs including Semaglutide (Wegovy NDA 215256, Ozempic NDA 209637) and Tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866).

Parathyroid hormone analog research led to anabolic osteoporosis peptide development. The VERT NEJM 2001 trial (Neer et al.) anchored Teriparatide (Forteo NDA 021318) FDA approval. Abaloparatide (Tymlos NDA 208743) followed with ACTIVE JAMA 2016 trial evidence. Sclerostin antibody research led to romosozumab (Evenity NDA 761062) with FRAME and ARCH Phase 3 evidence.

The Khavinson laboratory at St. Petersburg Institute of Bioregulation and Gerontology has conducted longevity peptide research since the 1970s. The program includes epitalon and other peptide bioregulators. The research base is primarily preclinical with some international human trial evidence in geriatric and longevity contexts.

The Sikiric laboratory at University of Zagreb has conducted BPC-157 research since the 1990s. The research base is primarily preclinical with rodent tendon healing, gastrointestinal cytoprotection, and other tissue repair models. BPC-157 operates as compounded preparation under AMA Code 1.1.5 framework in clinical contexts.

The Goldstein laboratory developed thymosin alpha-1. The compound received international approval as Zadaxin in approximately 35 countries with substantial hepatitis B and C clinical evidence. The compound is not FDA-approved in the US but operates as compounded preparation under AMA Code 1.1.5 framework. See Evidence Levels Explained for the PSI framework.

Joel Habener and Daniel Drucker conducted foundational GLP-1 discovery research. The Khavinson laboratory at St. Petersburg Institute of Bioregulation and Gerontology has conducted longevity peptide research since the 1970s. The Sikiric laboratory at University of Zagreb has conducted BPC-157 research since the 1990s. The Goldstein laboratory developed thymosin alpha-1 leading to international Zadaxin approval in approximately 35 countries. Multiple FDA-approved peptide drugs trace academic discovery origins. PSI documents the research landscape as historical reference.

PEPTIDE RESEARCH LANDSCAPE

At a Glance: The Peptide Research Landscape

Research Program	Subtitle	Animal Evidence	Human Evidence	Origin and Evidence
GLP-1 receptor agonist origins	Habener and Drucker laboratory foundational research	—	Strong	Joel Habener at Massachusetts General Hospital and Daniel Drucker at University of Toronto conducted foundational GLP-1 discovery research in the 1980s
Parathyroid hormone analog research	Forteo teriparatide and Tymlos abaloparatide development	—	Strong	PTH analog research led to anabolic osteoporosis peptide FDA approval anchored in VERT NEJM 2001 and ACTIVE JAMA 2016 Phase 3 trials
Sclerostin antibody research	Romosozumab Evenity FRAME and ARCH evidence	—	Strong	Sclerostin biology research led to romosozumab development. FRAME NEJM 2016 and ARCH NEJM 2017 anchored FDA approval with CV boxed warning
Khavinson laboratory longevity program	St. Petersburg Institute of Bioregulation since 1970s	—	Moderate	Khavinson laboratory conducts longevity peptide research including epitalon. Evidence base primarily preclinical with international geriatric trials
Sikiric BPC-157 research	University of Zagreb tissue repair research since 1990s	—	Limited	Sikiric laboratory conducts BPC-157 research with rodent tendon and gastrointestinal cytoprotection models. Operates as compounded under AMA Code 1.1.5
Goldstein thymosin alpha-1 program	International Zadaxin approval in approximately 35 countries	—	Moderate	Goldstein laboratory developed thymosin alpha-1 with substantial hepatitis B and C clinical evidence. Not FDA-approved in US, operates as compounded
Tesamorelin GHRH research	FDA-approved for HIV-associated lipodystrophy	—	Strong	Tesamorelin Egrifta NDA 022505 FDA-approved for HIV-associated lipodystrophy anchored in LIPO Phase 3 trial program
Bremelanotide melanocortin research	FDA-approved for HSDD in premenopausal women	—	Moderate	Bremelanotide Vyleesi NDA 210557 FDA-approved for HSDD in premenopausal women anchored in RECONNECT Phase 3 trial program

Six Things You Need to Know About Peptide Research History

This page covers the international peptide research landscape as historical reference. Section one covers GLP-1 receptor agonist origins in academic discovery. Section two covers parathyroid hormone and sclerostin antibody research leading to anabolic osteoporosis peptide FDA approvals. Section three covers Khavinson longevity research and Sikiric BPC-157 research programs. Section four covers Goldstein thymosin alpha-1 international Zadaxin approval and broader peptide research infrastructure.

GLP-1 Receptor Agonist Development Originated in Academic Discovery

GLP-1 receptor agonist development originated in academic laboratory discovery in the 1980s. Joel Habener at Massachusetts General Hospital conducted foundational glucagon and GLP-1 discovery research. Daniel Drucker at University of Toronto extended GLP-1 physiology and clinical translation.

Joel Habener at Massachusetts General Hospital conducted foundational research on glucagon gene structure and GLP-1 biology starting in the 1970s. The laboratory characterized the proglucagon gene and identified GLP-1 as a post-translational processing product. Daniel Drucker at University of Toronto conducted extensive GLP-1 physiology research starting in the 1980s. The Drucker laboratory characterized GLP-1 receptor signaling, incretin effects on insulin secretion, and clinical translation potential. The academic foundation enabled industrial development by Novo Nordisk and Eli Lilly leading to FDA-approved GLP-1 receptor agonists. Examples of FDA-approved GLP-1 receptor agonists include semaglutide (Wegovy NDA 215256 for chronic weight management, Ozempic NDA 209637 for type 2 diabetes), tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866 as dual GIP-GLP-1 receptor agonist), liraglutide (Saxenda, Victoza), and earlier-generation exenatide (Byetta, Bydureon). Cardiovascular outcomes evidence anchors many compounds including SELECT 2023 NEJM (Lincoff et al.) and SUSTAIN-6 NEJM 2016 (Marso et al.). The academic-to-industrial translation framework supports continued GLP-1 receptor agonist class expansion.

Parathyroid Hormone Analog Research Led to Anabolic Osteoporosis Peptides

Parathyroid hormone analog research led to anabolic osteoporosis peptide development. Teriparatide (Forteo NDA 021318) was the first FDA-approved anabolic osteoporosis peptide. Abaloparatide (Tymlos NDA 208743) followed with the ACTIVE Phase 3 trial.

Parathyroid hormone (PTH) biology research established the dual action of intermittent PTH exposure. Continuous PTH elevation causes bone resorption (as in primary hyperparathyroidism). Intermittent pulsatile PTH exposure causes bone formation. This pharmacologic principle enabled teriparatide development as recombinant PTH(1-34). The VERT NEJM 2001 trial (Neer et al. effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis) demonstrated fracture reduction and BMD improvement. FDA approved Forteo for postmenopausal osteoporosis with high fracture risk. Abaloparatide as a synthetic peptide related to parathyroid hormone-related protein followed with the ACTIVE JAMA 2016 trial (Miller et al. effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis). FDA approved Tymlos in 2017. Both compounds operate under AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG framework. The compounds have FDA-label-specified cumulative lifetime maximums with sequential anti-resorptive transition.

Sclerostin Antibody Research Led to Romosozumab Development

Sclerostin antibody research led to romosozumab development. Evenity romosozumab (NDA 761062) received FDA approval in 2019. The cardiovascular boxed warning was added based on ARCH NEJM 2017 trial findings.

Sclerostin biology research established sclerostin as a Wnt signaling inhibitor secreted by osteocytes. Sclerostin inhibition increases bone formation by promoting Wnt-mediated osteoblast activity. Sclerostin loss-of-function genetic conditions (sclerosteosis and Van Buchem disease) demonstrated the bone formation potential of sclerostin inhibition without causing pathologic conditions in the heterozygous state. This genetic foundation enabled romosozumab development as a humanized sclerostin antibody. The FRAME NEJM 2016 trial (Cosman et al.) demonstrated fracture reduction in postmenopausal women with osteoporosis. The ARCH NEJM 2017 trial (Saag et al. romosozumab or alendronate for fracture prevention in women with osteoporosis) demonstrated greater fracture reduction than alendronate but with increased cardiovascular adverse events. FDA approved Evenity in April 2019 with a cardiovascular boxed warning based on the ARCH trial cardiovascular safety findings. The compound uses fixed monthly schedule per FDA label. Sequential anti-resorptive transition follows completion per AACE/ACE 2020 and Endocrine Society 2019 CPGs.

The Khavinson Laboratory Conducts Longevity Peptide Research Since the 1970s

Vladimir Khavinson founded the St. Petersburg Institute of Bioregulation and Gerontology and has directed the laboratory's longevity peptide research program since the 1970s. The program developed the peptide bioregulator concept proposing short peptides as cellular regulators of gene expression and aging processes. The program developed multiple peptide compounds including epitalon (Ala-Glu-Asp-Gly), vilon, and others. Research includes preclinical rodent longevity studies and some international human trial evidence in geriatric contexts. The research base is primarily preclinical for most indications with limited Phase 1 through Phase 3 trial evidence by FDA standards. The compounds are not FDA-approved in the US. The compounds operate as compounded preparations under AMA Code of Medical Ethics 1.1.5 framework in US clinical contexts. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent. The PSI compound library provides evidence-tier classification per the four-tier framework (L1 preclinical, L2 animal studies, L3 human trials, L4 FDA-approved).

The Sikiric Laboratory Conducts BPC-157 Research Since the 1990s

Predrag Sikiric and colleagues at University of Zagreb have conducted BPC-157 (Body Protection Compound 157) research since the 1990s. The compound is a 15-amino-acid synthetic peptide derived from a protein found in gastric juice. The research program includes rodent tendon healing models, gastrointestinal cytoprotection models, vascular models, and other tissue repair contexts. The research base is primarily preclinical with rodent and other animal model studies. Limited human trial evidence exists. The compound is not FDA-approved. The compound operates as a compounded preparation in clinical contexts under AMA Code of Medical Ethics 1.1.5 framework. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding. BPC-157 is classified at L1 to L2 evidence tier on PSI per the four-tier framework depending on indication. Some indications have rodent model evidence supporting L2 classification. Other indications have only mechanistic or in vitro evidence supporting L1 classification. The compound is widely discussed in sports medicine and tissue repair contexts but the evidence base supports honest framing of preclinical foundation rather than clinical efficacy.

The Goldstein Laboratory Developed Thymosin Alpha-1 With International Approval

Allan L. Goldstein and colleagues isolated and characterized thymosin alpha-1 from thymic extracts starting in the 1970s. The 28-amino-acid peptide functions as an immune modulator with effects on T cell maturation, cytokine production, and immune response regulation. The compound was developed by SciClone Pharmaceuticals and other companies leading to international approval as Zadaxin. The international Zadaxin approval covers approximately 35 countries with substantial Phase 3 clinical evidence in hepatitis B and hepatitis C contexts. The clinical evidence places international thymosin alpha-1 at L3 human trials evidence tier per PSI framework. The compound is not FDA-approved in the US. The compound operates as a compounded preparation in US clinical contexts under AMA Code of Medical Ethics 1.1.5 framework. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding. Specialty coordination with immunology or infectious disease supports clinical contexts. PSI documents the international approval status as historical reference while maintaining honest framing of US regulatory status. See [The Compounding Pharmacy System](/education/the-compounding-pharmacy-system) for the regulatory framework.

GLP-1 receptor agonist class: from Habener and Drucker academic discovery to FDA-approved class

Academic-to-industrial translation framework anchoring chronic weight management and type 2 diabetes therapy

The academic foundation enabled industrial development by Novo Nordisk and Eli Lilly leading to FDA-approved GLP-1 receptor agonists. Examples include semaglutide (Wegovy NDA 215256 for chronic weight management, Ozempic NDA 209637 for type 2 diabetes), tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866 as dual GIP-GLP-1 receptor agonist), liraglutide (Saxenda for weight management, Victoza for type 2 diabetes), and earlier-generation exenatide (Byetta, Bydureon). The class spans multiple FDA approvals across chronic weight management and type 2 diabetes indications.

Cardiovascular outcomes evidence anchors many compounds including SELECT NEJM 2023 (Lincoff et al. semaglutide and cardiovascular outcomes in obesity without diabetes demonstrating approximately 20 percent MACE reduction), SUSTAIN-6 NEJM 2016 (Marso et al. semaglutide and cardiovascular outcomes in patients with type 2 diabetes), and LEADER NEJM 2016 (Marso et al. liraglutide and cardiovascular outcomes in type 2 diabetes). The academic-to-industrial translation framework supports continued GLP-1 receptor agonist class expansion. ADA 2024 Standards of Care provides the diagnostic and therapeutic framework for type 2 diabetes contexts.

Anabolic osteoporosis peptide research: PTH analogs and sclerostin antibody development

VERT, ACTIVE, FRAME, and ARCH Phase 3 evidence anchoring FDA approvals

Abaloparatide as a synthetic peptide related to parathyroid hormone-related protein followed with the ACTIVE JAMA 2016 trial (Miller et al. effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis). FDA approved Tymlos NDA 208743 in 2017. Both PTH analog compounds operate under AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG framework. Both compounds have FDA-label-specified cumulative lifetime maximums with sequential anti-resorptive transition.

Sclerostin biology research established sclerostin as a Wnt signaling inhibitor secreted by osteocytes. Sclerostin loss-of-function genetic conditions (sclerosteosis and Van Buchem disease) demonstrated the bone formation potential of sclerostin inhibition. The FRAME NEJM 2016 trial (Cosman et al.) and ARCH NEJM 2017 trial (Saag et al. romosozumab or alendronate for fracture prevention in women with osteoporosis) anchored romosozumab FDA approval. FDA approved Evenity NDA 761062 in April 2019 with a cardiovascular boxed warning based on the ARCH trial cardiovascular safety findings.

International peptide research: Khavinson, Sikiric, and Goldstein research programs

Academic research programs operating under AMA Code 1.1.5 framework in US clinical contexts

The Khavinson laboratory at St. Petersburg Institute of Bioregulation and Gerontology has conducted longevity peptide research since the 1970s under Vladimir Khavinson's direction. The program developed the peptide bioregulator concept proposing short peptides as cellular regulators of gene expression and aging processes. Compounds include epitalon (Ala-Glu-Asp-Gly), vilon, and others. Research includes preclinical rodent longevity studies and some international human trial evidence in geriatric contexts. The research base is primarily preclinical with limited Phase 1 through Phase 3 trial evidence by FDA standards. The compounds operate as compounded preparations under AMA Code 1.1.5 framework in US clinical contexts.

The Sikiric laboratory at University of Zagreb has conducted BPC-157 research since the 1990s. The compound is a 15-amino-acid synthetic peptide derived from a protein found in gastric juice. The research program includes rodent tendon healing, gastrointestinal cytoprotection, vascular, and other tissue repair models. The research base is primarily preclinical. Limited human trial evidence exists. The compound is classified at L1 to L2 evidence tier on PSI depending on indication. The compound operates as a compounded preparation in US clinical contexts under AMA Code 1.1.5 framework.

The Goldstein laboratory developed thymosin alpha-1 starting in the 1970s. The 28-amino-acid peptide functions as an immune modulator. The compound was developed by SciClone Pharmaceuticals and other companies leading to international approval as Zadaxin in approximately 35 countries with substantial Phase 3 clinical evidence in hepatitis B and hepatitis C contexts. The clinical evidence places international thymosin alpha-1 at L3 human trials evidence tier per PSI framework. The compound is not FDA-approved in the US. The compound operates as a compounded preparation in US clinical contexts under AMA Code 1.1.5 framework.

Research Suggests

Direction

GLP-1 receptor agonist development originated in Habener and Drucker academic laboratories in the 1980s. The academic foundation enabled industrial development by Novo Nordisk and Eli Lilly leading to FDA-approved GLP-1 receptor agonists across chronic weight management and type 2 diabetes indications. Parathyroid hormone analog research led to teriparatide (Forteo NDA 021318) and abaloparatide (Tymlos NDA 208743) FDA approvals anchored in VERT NEJM 2001 and ACTIVE JAMA 2016 Phase 3 trials. Sclerostin antibody research led to romosozumab (Evenity NDA 761062 with cardiovascular boxed warning) anchored in FRAME NEJM 2016 and ARCH NEJM 2017. The Khavinson laboratory at St. Petersburg Institute of Bioregulation and Gerontology has conducted longevity peptide research since the 1970s. The Sikiric laboratory at University of Zagreb has conducted BPC-157 research since the 1990s. The Goldstein laboratory developed thymosin alpha-1 leading to international Zadaxin approval in approximately 35 countries.

Strongest evidence

FDA-approved peptide drugs anchored in Phase 3 trial evidence provide the strongest evidence framework across the peptide research landscape.

FDA-approved peptide drugs with completed FDA pre-market review provide the strongest evidence anchoring. Examples include the GLP-1 receptor agonist class anchored in Phase 3 trial evidence: SELECT 2023 NEJM (Lincoff et al. semaglutide cardiovascular outcomes), SUSTAIN-6 NEJM 2016 (Marso et al. semaglutide cardiovascular outcomes in T2D), SURMOUNT-1 NEJM 2022 (Jastreboff et al. tirzepatide weight management), LEADER NEJM 2016 (Marso et al. liraglutide cardiovascular outcomes). The anabolic osteoporosis peptide class is anchored in VERT NEJM 2001 (Neer et al. teriparatide fracture reduction), ACTIVE JAMA 2016 (Miller et al. abaloparatide fracture reduction), FRAME NEJM 2016 (Cosman et al. romosozumab fracture reduction), and ARCH NEJM 2017 (Saag et al. romosozumab vs alendronate). Tesamorelin Egrifta NDA 022505 anchored in LIPO Phase 3 trials for HIV-associated lipodystrophy. Bremelanotide Vyleesi NDA 210557 anchored in RECONNECT Phase 3 trials for HSDD in premenopausal women. International approvals provide L3 human trials evidence anchoring including thymosin alpha-1 Zadaxin in 35 countries.

Limitations

International academic research programs vary substantially in evidence base. Compounded preparations operate outside FDA pre-market approval.

International academic peptide research programs vary substantially in evidence base across compounds and indications. The Khavinson laboratory longevity research program operates at L1 to L2 evidence tier on PSI for most compounds with primarily preclinical rodent evidence and limited international Phase 1 through Phase 3 evidence. The Sikiric BPC-157 research program operates at L1 to L2 evidence tier with primarily preclinical rodent tendon and gastrointestinal models. The Goldstein thymosin alpha-1 program operates at L3 human trials evidence tier in international Zadaxin approval contexts (approximately 35 countries) but is not FDA-approved in the US. Most international academic research programs include compounds that operate as compounded preparations in US clinical contexts under AMA Code of Medical Ethics 1.1.5 framework. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent. Evidence-tier framework supports honest claim communication across compounds with varying evidence quality.

Assessment

The peptide research landscape spans academic-to-industrial translation, international research programs, and ongoing clinical development across multiple indications.

PSI's reading: the peptide research landscape spans academic-to-industrial translation, international academic research programs, and ongoing clinical development across the indication spectrum. The GLP-1 receptor agonist class demonstrates successful academic-to-industrial translation from Habener and Drucker foundational research to multiple FDA-approved drugs with cardiovascular outcomes evidence. The anabolic osteoporosis peptide class demonstrates similar translation from PTH biology and sclerostin biology research to FDA approvals. International academic research programs (Khavinson laboratory longevity, Sikiric BPC-157, Goldstein thymosin alpha-1) contribute additional evidence base with varying clinical translation status. The PSI four-tier evidence framework provides transparent classification across the landscape (L1 preclinical, L2 animal studies, L3 human trials, L4 FDA-approved). Every compound on PSI declares one locked evidence level traceable to peer-reviewed primary sources. Specialty coordination supports indication-specific evaluation across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health. The PSI physician directory provides verified physicians applying FDA prescribing information and AMA Code 1.1.5 framework to peptide therapy clinical decisions.

How to Approach Your Decision

Limitations and Caveats

International academic research programs vary substantially in evidence base. Khavinson, Sikiric, and other programs operate at varying evidence tiers.
Compounded peptide preparations operate outside FDA pre-market approval. AMA Code 1.1.5 framework documentation applies for clinical contexts.
International approvals do not equal FDA approval. Zadaxin thymosin alpha-1 in 35 countries is classified L3 human trials rather than L4 FDA-approved.
Academic research evidence varies by indication. Some compounds have stronger evidence in specific indications than others.
Evidence-tier classification reflects current evidence base. New trials may shift compounds to higher evidence tiers over time.
Self-sourcing of peptide preparations operates outside the validated clinical practice framework. Research-grade products labeled not for human use are not a legal substitute.
The peptide research landscape continues to evolve. New FDA approvals expand the class. New academic research adds evidence.
Specialty coordination supports comprehensive evidence interpretation. No single research program covers the full peptide therapy spectrum.

What's Marketed vs What's Studied

7 common claims, corrected.

“All peptide therapy has academic research foundations equivalent to GLP-1 receptor agonists.”

Academic research foundations vary substantially across compounds. GLP-1 receptor agonists trace back to Habener and Drucker foundational research with multiple FDA approvals. Other compounds operate at lower evidence tiers including L1 preclinical or L2 animal studies. PSI four-tier framework provides transparent classification.

“International approvals are equivalent to FDA approval.”

International approvals like Zadaxin thymosin alpha-1 in approximately 35 countries are noted but do not equal FDA approval. PSI classifies international-approval compounds at L3 human trials evidence tier rather than L4 FDA-approved. L4 requires US FDA pre-market review specifically.

“BPC-157 has FDA approval based on Sikiric laboratory research.”

BPC-157 is not FDA-approved. The Sikiric laboratory research program at University of Zagreb conducts primarily preclinical rodent and other animal model research. The compound operates as a compounded preparation in US clinical contexts under AMA Code 1.1.5 framework. Evidence tier is L1 to L2 depending on indication.

“Khavinson laboratory peptide bioregulators have Phase 3 trial evidence supporting FDA approval.”

Khavinson laboratory peptide bioregulators including epitalon operate primarily at L1 to L2 evidence tier with primarily preclinical rodent longevity model evidence. Limited international human trial evidence exists in geriatric contexts. The compounds are not FDA-approved and operate as compounded preparations under AMA Code 1.1.5 framework.

“Romosozumab Evenity was approved without safety concerns.”

FDA added a cardiovascular boxed warning to Evenity in April 2019 based on ARCH NEJM 2017 trial findings demonstrating increased serious cardiovascular adverse events compared to alendronate comparator. The boxed warning affects protocol framework. Specialty cardiology coordination supports the framework.

“All peptide research conducted internationally is conducted to FDA Good Clinical Practice standards.”

International peptide research varies in conduct standards. ICH E6 Good Clinical Practice provides unified standards for ICH regions including US, EU, Japan, Canada, Switzerland, and others. International research outside ICH regions may not follow ICH E6 standards. PubMed-indexed peer-reviewed research provides verification framework. CONSORT, STROBE, and PRISMA reporting standards support transparent communication.

“Academic discovery research translates directly to FDA approval without industrial development.”

Academic-to-industrial translation typically involves industrial development by pharmaceutical companies. GLP-1 receptor agonists involved Novo Nordisk and Eli Lilly industrial development beyond Habener and Drucker academic research. The full development process includes preclinical safety pharmacology, Phase 1 through Phase 3 trials, and FDA pre-market review per 21 CFR 312 and 21 CFR 314.

Common Questions

Where did GLP-1 receptor agonists come from?

GLP-1 receptor agonists originated in academic laboratory discovery in the 1980s. Joel Habener at Massachusetts General Hospital conducted foundational glucagon and GLP-1 discovery research. Daniel Drucker at University of Toronto extended GLP-1 physiology and clinical translation research. The academic foundation enabled industrial development by Novo Nordisk and Eli Lilly leading to FDA-approved drugs.

What is the Khavinson laboratory?

The Khavinson laboratory at St. Petersburg Institute of Bioregulation and Gerontology has conducted longevity peptide research since the 1970s under Vladimir Khavinson's direction. The program developed the peptide bioregulator concept and compounds including epitalon. Research base is primarily preclinical with some international geriatric trial evidence.

What is the Sikiric BPC-157 research program?

The Sikiric laboratory at University of Zagreb has conducted BPC-157 research since the 1990s. BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in gastric juice. The research program includes rodent tendon healing, gastrointestinal cytoprotection, and other tissue repair models. The research base is primarily preclinical.

What is thymosin alpha-1 and where did it come from?

Thymosin alpha-1 is a 28-amino-acid peptide isolated from thymic extracts by Allan Goldstein and colleagues starting in the 1970s. The compound functions as an immune modulator. SciClone Pharmaceuticals developed the compound leading to international approval as Zadaxin in approximately 35 countries with hepatitis B and C clinical evidence.

Is thymosin alpha-1 FDA-approved?

Thymosin alpha-1 is not FDA-approved in the US. The compound received international approval as Zadaxin in approximately 35 countries with substantial Phase 3 clinical evidence. The compound operates as a compounded preparation in US clinical contexts under AMA Code of Medical Ethics 1.1.5 framework. PSI classifies the compound at L3 human trials evidence tier.

Where did parathyroid hormone analog research come from?

Parathyroid hormone (PTH) biology research established the dual action of intermittent PTH exposure. Continuous PTH elevation causes bone resorption. Intermittent pulsatile PTH exposure causes bone formation. This pharmacologic principle enabled teriparatide development. VERT NEJM 2001 anchored Forteo FDA approval. ACTIVE JAMA 2016 anchored Tymlos FDA approval.

What is sclerostin and how did it lead to romosozumab?

Sclerostin is a Wnt signaling inhibitor secreted by osteocytes. Sclerostin inhibition increases bone formation by promoting Wnt-mediated osteoblast activity. Sclerostin loss-of-function genetic conditions demonstrated the bone formation potential. The genetic foundation enabled romosozumab development. FRAME NEJM 2016 and ARCH NEJM 2017 anchored Evenity FDA approval with cardiovascular boxed warning.

What is the evidence base for compounded BPC-157?

Compounded BPC-157 evidence base is primarily preclinical with rodent tendon healing, gastrointestinal cytoprotection, and other tissue repair model evidence from the Sikiric laboratory at University of Zagreb. PSI classifies BPC-157 at L1 to L2 evidence tier depending on indication. The compound operates as compounded preparation under AMA Code 1.1.5 framework.

What is the evidence base for compounded thymosin alpha-1?

Compounded thymosin alpha-1 evidence base includes substantial international clinical evidence in hepatitis B and hepatitis C contexts supporting Zadaxin approval in approximately 35 countries. PSI classifies international thymosin alpha-1 at L3 human trials evidence tier. The compound operates as compounded preparation in US clinical contexts under AMA Code 1.1.5 framework.

What is the evidence base for compounded epitalon?

Compounded epitalon (Ala-Glu-Asp-Gly tetrapeptide) evidence base is primarily preclinical with rodent longevity model evidence from the Khavinson laboratory. Some international human trial evidence exists in geriatric contexts. PSI classifies epitalon at L1 to L2 evidence tier. The compound operates as compounded preparation under AMA Code 1.1.5 framework.

How do academic discoveries become FDA-approved drugs?

Academic-to-industrial translation typically involves industrial development by pharmaceutical companies. The full development process includes preclinical safety pharmacology per FDA guidance, Phase 1 first-in-human safety, Phase 2 dose-finding, and Phase 3 pivotal efficacy and safety trials. The process operates under 21 CFR 312 (IND framework) and 21 CFR 314 (NDA framework) with ICH E6 Good Clinical Practice.

What is ICH E6 Good Clinical Practice?

ICH E6 Good Clinical Practice is the International Council for Harmonisation guideline for clinical trial design, conduct, monitoring, recording, analysis, and reporting. The guideline provides unified standards for the European Union, Japan, United States, Canada, Switzerland, and other ICH regions. FDA-approved peptide drugs route through ICH E6-compliant trials.

What is the PSI four-tier evidence framework?

PSI uses a four-tier evidence framework distinguishing preclinical (L1), animal studies (L2), human trials (L3), and FDA-approved (L4) compounds. Visitor-facing labels are FDA Approved, Human Trials, Animal Studies, and Preclinical. Every compound on PSI declares one locked evidence level traceable to peer-reviewed primary sources. See Evidence Levels Explained for the methodology.

Where are PubMed-indexed peptide research sources?

PubMed at pubmed.ncbi.nlm.nih.gov is the NIH database of biomedical literature operated by the National Library of Medicine. The database indexes over 35 million biomedical citations from MEDLINE, life science journals, and online books. Every claim on PSI links to PubMed-indexed peer-reviewed primary sources documented in the data layer.

Does PSI provide research for compounded peptide therapy decisions?

PSI provides evidence-graded compound documentation including primary-source citations from PubMed-indexed peer-reviewed research. The PSI four-tier evidence framework supports honest claim communication. Compounded peptide therapy decisions operate under AMA Code of Medical Ethics 1.1.5 framework with documented risk-benefit assessment by the prescribing physician.

How does the peptide research landscape continue to evolve?

New FDA approvals expand the FDA-approved peptide drug class. New academic research adds evidence across the indication spectrum. New trials may shift compounds to higher evidence tiers over time. PSI tracks regulatory updates and new peer-reviewed primary sources per the Editorial Standards review cadence.

Sourcing Checklist

Verify primary-source citations through PubMed-indexed peer-reviewed research.
Every claim on PSI links to PubMed-indexed peer-reviewed primary sources documented in the data layer. PubMed at pubmed.ncbi.nlm.nih.gov supports verification.
Check PSI four-tier evidence framework classification per compound.
L1 preclinical, L2 animal studies, L3 human trials, L4 FDA-approved. Visitor-facing labels are FDA Approved, Human Trials, Animal Studies, Preclinical.
Distinguish FDA-approved indications from off-label and compounded contexts.
FDA approval is indication-specific. Off-label use operates under AMA Code 1.1.5 framework. Compounded preparations operate under FDA Compounding Quality Act of 2013.
Note international approvals where applicable.
International approvals like Zadaxin thymosin alpha-1 in 35 countries do not equal FDA approval. PSI classifies international-approval compounds at L3 human trials evidence tier.
Review reporting standard compliance for primary-source trials.
CONSORT for randomized trials, STROBE for observational studies, PRISMA for systematic reviews per ICMJE Uniform Requirements.
Assess risk of bias using Cochrane Risk of Bias 2 tool for randomized trials.
Five domains: randomization process, deviations from interventions, missing outcome data, measurement of outcome, selection of reported result.
Consider boxed warnings and post-marketing safety signals.
Evenity romosozumab cardiovascular boxed warning reflects ARCH NEJM 2017 findings. FDA MedWatch surveillance supports ongoing safety signal monitoring.
Discuss specific research findings and clinical application with prescribing physician.
Historical research reference does not substitute for prescribing physician evaluation. Specialty coordination supports complex contexts.
Expect specialty coordination for indication-specific contexts.
Endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health support indication-appropriate evaluation.

Regulatory Context

The peptide research landscape continues to evolve. New FDA approvals expand the FDA-approved peptide drug class. New academic research adds evidence base. International approvals may shift evidence-tier classification per PSI framework. New cardiovascular outcomes trials extend FDA-approved class evidence. New society Clinical Practice Guidelines incorporate emerging evidence. PSI tracks regulatory updates and new peer-reviewed primary sources per the Editorial Standards review cadence including FDA approvals, Phase 3 trial publications, society CPG updates, and PubMed-indexed new evidence.

Comparison

Research Program	Location	Era	Evidence Tier
Habener laboratory GLP-1 discovery	Massachusetts General Hospital	1970s onward	Translated to L4 FDA-approved class
Drucker laboratory GLP-1 physiology	University of Toronto	1980s onward	Translated to L4 FDA-approved class
PTH analog research	Multiple academic and industrial programs	1980s-1990s	L4 FDA-approved (Forteo, Tymlos)
Sclerostin antibody research	Multiple academic and industrial programs	1990s-2000s	L4 FDA-approved (Evenity with CV BBW)
Khavinson laboratory longevity	St. Petersburg Institute of Bioregulation	1970s onward	L1 to L2 (primarily preclinical)
Sikiric laboratory BPC-157	University of Zagreb	1990s onward	L1 to L2 (primarily preclinical)
Goldstein thymosin alpha-1	Industrial development	1970s onward	L3 (international Zadaxin approval)
Tesamorelin GHRH research	Industrial development	1990s-2000s	L4 FDA-approved for HIV lipodystrophy

Who This Applies To

· Patient seeking historical context for FDA-approved peptide therapy options.
· Adult researching academic foundations of GLP-1 receptor agonist therapy class.
· Patient considering compounded peptide therapy and reviewing the evidence base.
· Researcher reviewing international peptide research programs across multiple laboratories.
· Adult considering compounded thymosin alpha-1 and reviewing Goldstein laboratory research history.
· Patient considering compounded BPC-157 and reviewing Sikiric laboratory research base.
· Adult considering compounded longevity peptide therapy and reviewing Khavinson laboratory research.
· Patient evaluating evidence-tier classification across the peptide research landscape.
· Researcher seeking PubMed-indexed primary source verification for peptide research claims.
· Adult reviewing the PSI four-tier evidence framework application across compound classes.

Verdict

Peptide therapy traces back to multiple academic laboratories worldwide. The GLP-1 receptor agonist class translates Habener and Drucker academic discovery to FDA-approved drugs. The anabolic osteoporosis peptide class derives from PTH and sclerostin biology research. International research programs include Khavinson laboratory longevity research, Sikiric BPC-157 research, and Goldstein thymosin alpha-1 program. The PSI four-tier evidence framework supports transparent claim communication. Compounded preparations operate under AMA Code 1.1.5 framework in US clinical contexts.

In Plain Terms

Peptide therapy comes from many academic laboratories worldwide. GLP-1 drugs like Ozempic and Wegovy trace back to Joel Habener and Daniel Drucker research in the 1980s. Osteoporosis peptides like Forteo come from parathyroid hormone research. The Khavinson lab in St. Petersburg has worked on longevity peptides since the 1970s. The Sikiric lab in Zagreb has worked on BPC-157 since the 1990s. Thymosin alpha-1 is approved in about 35 countries as Zadaxin. PSI classifies each compound by evidence quality from preclinical to FDA-approved.

Many universities and research labs have studied peptides over decades. Some research led to FDA-approved drugs like Ozempic and Forteo. Other research is mostly in animals or in early human trials. Different evidence levels apply to different peptides. PSI tells you which evidence level applies to each compound. Talk to your doctor about which peptides have the right evidence base for your situation.

Historical research reference supports informed discussion with prescribing physicians but does not substitute for physician clinical judgment in your specific context. The PSI physician directory provides verified physicians applying FDA prescribing information and AMA Code 1.1.5 framework to peptide therapy clinical decisions across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Patient seeking historical context for FDA-approved peptide therapy
· Adult researching GLP-1 receptor agonist academic foundations
· Patient considering compounded peptide therapy and evidence base
· Researcher reviewing international peptide research programs
· Adult considering compounded thymosin alpha-1 and Goldstein research
· Patient considering compounded BPC-157 and Sikiric research base
· Adult considering compounded longevity peptide and Khavinson research
· Patient evaluating evidence-tier classification across compounds
· Researcher seeking PubMed primary source verification
· Adult reviewing PSI four-tier framework application

Important Context

This page is educational and does not constitute medical advice. The information presented reflects published peer-reviewed research from international academic laboratories including the Habener laboratory at Massachusetts General Hospital, the Drucker laboratory at University of Toronto, the Khavinson laboratory at St. Petersburg Institute of Bioregulation and Gerontology, the Sikiric laboratory at University of Zagreb, the Goldstein laboratory research program, and other academic and industrial research contributing to FDA-approved peptide drug development. The information includes FDA prescribing information for FDA-approved peptide drugs, peer-reviewed Phase 3 trial evidence (SELECT 2023 NEJM, SUSTAIN-6 NEJM 2016, SURMOUNT-1 NEJM 2022, VERT NEJM 2001, ACTIVE JAMA 2016, FRAME NEJM 2016, ARCH NEJM 2017, LEADER NEJM 2016), society Clinical Practice Guidelines (AACE/ACE 2020 Postmenopausal Osteoporosis CPG, Endocrine Society 2019 CPG, ADA 2024 Standards of Care), AMA Code of Medical Ethics 1.1.5 framework, and FDA Compounding Quality Act of 2013.

Your physician will evaluate the evidence base for any specific peptide therapy in the context of your individual clinical situation. The framework described here is general historical reference and does not substitute for individualized clinical judgment. Specialty coordination supports complex contexts across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health.

Historical research reference does not substitute for prescribing physician evaluation and clinical oversight. Self-sourcing of peptide preparations outside physician prescribing pathways operates outside the validated clinical practice framework. Research-grade peptide products labeled not for human use are not a legal substitute for physician-prescribed FDA-approved or compounded therapy.

Educational content only. This page provides historical reference for the international peptide research landscape. PSI does not provide personalized clinical recommendations. Dosing should be determined by a qualified physician who can evaluate your individual situation. Discuss specific research findings and clinical application with your prescribing physician before initiating any peptide therapy.

Sources and Citations

[1] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[2] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine · 2016 · DOI
[3] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine · 2022 · DOI
[4] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis (VERT trial) · New England Journal of Medicine · 2001 · DOI
[5] Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis (ACTIVE trial) · JAMA · 2016 · DOI
[6] Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis (FRAME trial) · New England Journal of Medicine · 2016 · DOI
[7] Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis (ARCH trial) · New England Journal of Medicine · 2017 · DOI
[8] FDA Prescribing Information: Wegovy (semaglutide) injection · 2024 · FDA NDA 215256 · Source
[9] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[10] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[11] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[12] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2020 Update · Endocrine Practice · 2020 · DOI

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.